01—Abstract
Summary
Summary of the 10-Q filed August 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) reported $6.95 billiona in total revenues for the second quarter of 2024, a 5% increase compared to the same period last year.
This growth was primarily driven by strong performance in HIV, Oncology, and Liver Disease segments. Diluted earnings per share (EPS) for the quarter were $1.29b, a significant increase from $0.83 in Q2 2023, reflecting improved revenues and lower operating expenses. Despite a strong Q2 performance, the six-month period ending June 30, 2024, showed a net loss of $2.56 billion.
This was largely attributable to a significant acquired in-process R&D charge of $3.9 billionc related to the CymaBay acquisition and a $2.4 billion impairment charge on IPR&D assets for Trodelvy's NSCLC indication. The company also reported a decrease in cash and cash equivalents, primarily due to the CymaBay acquisition and dividend payments. Gilead's balance sheet remains robust, but investors should monitor the impact of significant R&D charges and ongoing litigation.
02—Key points
Key Highlights
- Total revenues increased by 5% year-over-year to $6.95 billion for the second quarter of 2024, driven by growth in HIV, Oncology, and Liver Disease product sales.
- Diluted earnings per share (EPS) for the second quarter of 2024 was $1.29, a substantial increase from $0.83 in the prior year's second quarter.
- The six-month period ending June 30, 2024, resulted in a net loss of $2.56 billion, primarily due to significant R&D charges and impairments.
- A major factor impacting the six-month results was a $3.9 billion acquired in-process R&D expense related to the acquisition of CymaBay Therapeutics.
- The company recorded a $2.4 billion impairment charge related to Trodelvy's non-small cell lung cancer (NSCLC) indication following disappointing Phase 3 study results.
- Cash and cash equivalents decreased significantly from $6.09 billion at the beginning of the year to $2.77 billion by the end of the second quarter, largely due to acquisitions and dividend payments.
- Gilead continues to face significant legal proceedings, including patent litigation with generic manufacturers and antitrust and product liability lawsuits.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Gilead Sciences, Inc. kept $0.23.
- Revenue$6.95B100.0%
- Cost of revenue−$1.54B22.2%
- Gross profit$5.41B77.8%
- Operating costs−$2.77B39.8%
- Operating income$2.64B38.0%
- Interest, other & tax−$1.03B14.8%
- Net income$1.61B23.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 8, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $6.95B$6.60B | +5.4% |
| Cost of Revenue | $1.54B$1.44B | +7.1% |
| Gross Profit | $5.41B$5.16B | +4.9% |
| SG&A Expenses | $1.38B$1.85B | −25.5% |
| Operating Expenses | $4.31B$4.93B | −12.7% |
| Operating Income | $2.64B$1.67B | +58.8% |
| Net Income | $1.61B$1.04B | +54.4% |
| EPS (Basic) | $1.29$0.84 | +53.6% |
| EPS (Diluted) | $1.29$0.83 | +55.4% |
| Shares Outstanding (Basic) | 1.25B1.25B | −0.2% |
| Shares Outstanding (Diluted) | 1.25B1.26B | −0.6% |
05—Questions
Frequently Asked Questions
What drove the revenue growth in the second quarter of 2024?
Revenue growth in Q2 2024 was primarily driven by increased product sales in the HIV, Oncology, and Liver Disease segments. Key contributors included strong performance from Biktarvy, Yescarta, Tecartus, and Trodelvy, as well as increased sales in the Liver Disease portfolio.
What are the significant factors impacting Gilead's net income/loss for the first six months of 2024?
The net loss for the first six months of 2024 was significantly impacted by two major non-recurring items: a $3.9 billion acquired in-process R&D expense related to the acquisition of CymaBay Therapeutics and a $2.4 billion impairment charge on intangible assets associated with the Trodelvy indication for non-small cell lung cancer.
How has the acquisition of CymaBay Therapeutics impacted Gilead's financial position?
The acquisition of CymaBay, completed in March 2024 for $3.9 billion (net cash paid), significantly impacted the six-month financial results due to the substantial acquired in-process R&D expense. It also contributed to a decrease in cash and cash equivalents.
What is the status of Gilead's legal proceedings?
Gilead is involved in several significant legal proceedings, including patent infringement lawsuits related to generic versions of Symtuza, Biktarvy, and Genvoya, and ongoing antitrust and product liability litigation concerning various HIV medications. The company also had a favorable jury verdict in a patent infringement case with the U.S. federal government related to PrEP, though an appeal has been filed. While many of these matters are ongoing, Gilead believes it has strong defenses.
06—Continue